$CRDF is steadily closing in on its cash value. The question I have now is what is the estimated net value after subtracting liabilities and adding assets? How much is onvansertib worth? Basing the value entirely on the US commercial applications is erroneous, I believe. Mirati licensed its own mutant KRAS targeted molecule, still in trial, internationally. The same could potentially occur for Cardiff Oncology’s molecule, assuming the license they hold allows them to do so.